Treatment of non-Hodgkin lymphoma.

Abstract

Preliminary results of new therapies in the areas of cytotoxic agents and immunotherapy for advanced indolent lymphomas have been encouraging. Long-term follow-up on high-dose therapy suggests a potential role for this modality in this group of lymphomas. In aggressive lymphomas, CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) continues to hold ground as first-line therapy when compared against other regimens. Several studies reinforce past findings that patients with chemosensitive relapse are better candidates for high-dose therapy. In relapsed or refractory disease, selected compounds appear to have activity as single agents and others have shown activity in combination therapy. Despite high treatment-related mortality rates, allogeneic transplantation in relapsed aggressive lymphoma warrants further investigation. Last, as patients are surviving longer, complications of therapy are having to be addressed.

Statistics

0100200300'99'01'03'05'07'09'11'13'15'17
Citations per Year

287 Citations

Semantic Scholar estimates that this publication has 287 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Hauke2000TreatmentON, title={Treatment of non-Hodgkin lymphoma.}, author={Ralph J . Hauke and James Olen Armitage}, journal={Current opinion in oncology}, year={2000}, volume={12 5}, pages={412-8} }